Registry for MEN2 and Familial Medullary Thyroid Cancer (FMTC) Patients

M.D. Anderson Cancer Center in Houston, Texas, is asking for patients with MEN2 and FMTC (Familial Medullary Thyroid Cancer) to enroll in the Genetics of Endocrine Neoplasias Registry.

The registry is open to patients everywhere in the world.

MEN2 and FMTC are rare,  which has made it difficult for researchers to study them.

The registry being built at M.D. Anderson is meant to collect medical and family history information on people from all over the world who have MEN2 or FMTC.

Having many people involved not only helps researchers learn more about the disease, but it also helps to support future research studies on genetic, medical, and psychosocial factors that impact health outcomes. 

Any individual with a diagnosis of Multiple Endocrine Neoplasia type 2 (MEN2) or Familial Medullary Thyroid Cancer (FMTC) is eligible for this study.

Individuals who participate in the registry will be asked to complete questionnaires about their medical and family histories.

Other optional parts of the study include: signing a release for medical records, donating a saliva sample, releasing tumor tissue blocks which have been stored from previous surgeries, sharing information about the registry with family members, and completing yearly follow-up questionnaires.

Participation in the registry can be completed via telephone, mail, or Internet.

For more information about this study, please contact the research study coordinator at 713-792-7642 or email genr@mdanderson.org